A carregar...
Ibrutinib therapy increases T cell repertoire diversity in patients with chronic lymphocytic leukemia
The BTK inhibitor ibrutinib is a highly effective, new targeted therapy for chronic lymphocytic leukemia (CLL) that thwarts leukemia cell survival, growth, and tissue homing. The effects of ibrutinib treatment on the T cell compartment, which is clonally expanded and thought to support the growth of...
Na minha lista:
| Publicado no: | J Immunol |
|---|---|
| Main Authors: | , , , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5296363/ https://ncbi.nlm.nih.gov/pubmed/28077600 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4049/jimmunol.1601190 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|